Loading clinical trials...
Loading clinical trials...
A Phase I Study of Safety, Tolerability, Pharmacokinetic and Pharmacodynamics Property of Orally Administered APG-2575 in Patients With Hematologic Malignancies
Conditions
Interventions
APG-2575
Locations
5
United States
Mayo Clinic
Jacksonville, Florida, United States
Duke Unviersity
Durham, North Carolina, United States
MDACC
Houston, Texas, United States
St. Vincent Hospital
Fitzroy, Victoria, Australia
Epworth Healthcare
Richmond, Victoria, Australia
Start Date
August 7, 2018
Primary Completion Date
September 15, 2024
Completion Date
February 15, 2025
Last Updated
August 19, 2024
NCT06823167
NCT03838926
NCT05011422
NCT07285668
NCT07195916
NCT07186192
Lead Sponsor
Ascentage Pharma Group Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions